Newsroom

October 2017

• Press release Oct 28, 2017

  Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a

  PARADIGMS data also show patients treated with Gilenya had significantly fewer new brain lesions vs. those on interferon beta-1a   Currently there are no specifically approved disease…
• Press release Oct 27, 2017

  Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review

  Comprehensive data package demonstrates that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of safety, efficacy and quality Pegfilgrastim is a long-acting version of…
• Press release Oct 25, 2017

  Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS

  Full data from the pivotal Phase III PARADIGMS study of Gilenya® (fingolimod) in pediatric MS will be presented for the first time   With 54 accepted abstracts, Novartis presence spans from…
• Press release Oct 24, 2017

  Novartis: au troisième trimestre, croissance du chiffre d'affaires et du résultat dans toutes les divisions

  Chiffre d'affaires net en hausse de 2% (tcc[1], +2% USD), avec une croissance dans toutes les divisions: Cosentyx (USD 556 millions, +83% tcc) a affiché une forte hausse dans toutes ses…
• Press release Oct 24, 2017

  Novartis steigert im dritten Quartal Umsatz und Gewinn in allen Divisionen

  Der Nettoumsatz steigt mit einem Wachstum in allen Divisionen um 2% (kWk[1], +2% USD): Cosentyx (USD 556 Millionen, +83% kWk) wächst in allen Indikationen stark Entresto (USD 128 Millionen, +…
• Press release Oct 24, 2017

  Novartis delivered growth on top and bottom line in all divisions in Q3

  Net sales grew 2% (cc[1], +2% USD), with growth in all divisions: Cosentyx (USD 556 million, +83% cc) showed strong growth across all indications Entresto (USD 128 million, +138% cc) grew…
• Press release Oct 23, 2017

  Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients

  Breakthrough Therapy Designation based on Phase III study showing the three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo1…
• 
  Story Oct 19, 2017 Discovery

  Eye on patients, mind on innovation

  New Global Head of Ophthalmology Research sees the eye as a frontier of biomedical research.

• 
  Story Oct 18, 2017 From Our Labs

  Bringing virtual reality to the lab

  Novartis researchers want to use the technology to help them design new drugs.

• Press release Oct 18, 2017

  Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)

  Nearly 70% of patients maintained platelet counts of >=30×109/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding More than one-third of patients permanently…
• Featured News Oct 16, 2017

  Novartis to host stakeholder dialogue on ways to improve access to healthcare in lower-income countries

  The event will take place on November 21 in Basel.

• 
  Story Oct 13, 2017 Patient Perspectives

  A fitness trainer strives to keep his mother’s mind limber

  On Friday nights, Juan Pedro García Hernández goes dancing – but for rest of the time he’s taking care of his mother.